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Abstract
OBJECTIVES: Left ventricular (LV) diastolic dysfunction after aortic valve replacement (AVR) carries a substantial risk of development of
heart failure and reduced survival. In addition to echocardiography, B-type natriuretic peptide (BNP) provides a powerful incremental as-
sessment of diastolic function. This study evaluates BNP as a marker of LV diastolic dysfunction in a cohort of patients with preserved LV
ejection fraction who underwent AVR for pure aortic stenosis and the relationship between BNP values and the grade of LV diastolic dys-
function.
METHODS: A total of 113 patients were included in the study. Echocardiographic evaluation was performed preoperatively, 5 days post-
operatively and at 12-month follow-up, to assess LV dimensional and functional parameters. Diastolic function was labelled as normal,
mild, moderate or severe dysfunction. Concomitantly, BNP levels were evaluated.
RESULTS: Mild to severe diastolic dysfunction occurred preoperatively in all patients. At 12-month follow-up, 65 (62.5%) patients had mild
and 25 (24.1%) moderate to severe diastolic dysfunction. BNP values, categorized for quartile distribution, correlated with diastolic dys-
function grade (P < 0.001 for each comparison). At receiver operating characteristic analysis, the BNP level of 120 pg/ml was 91% sensitive
and 85% speciﬁc for diastolic disease, while 300 pg/ml was 80% sensitive and 91% speciﬁc for moderate or severe diastolic dysfunction.
Twelve months after AVR, BNP values were strongly correlated with the signiﬁcant echocardiographic parameters suggestive of diastolic
dysfunction (P ≤ 0.006 in all cases).
CONCLUSIONS: The BNP level following AVR is related to diastolic disease severity and may complement echocardiographic evaluation
when symptoms are unclear and LV function is difﬁcult to interpret.
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INTRODUCTION
Aortic stenosis (AS) is associated with left ventricular (LV) hyper-
trophy, which involves diastolic and systolic disturbances. Aortic
valve replacement (AVR) leads to early postoperative haemo-
dynamic and metabolic recovery, contributing to the improve-
ment in LV function and geometry. A successful AVR often results
in persistent LV hypertrophy and/or in LV outﬂow tract obstruc-
tion, which jeopardizes systolic and diastolic function recovery
[1–4]. Persistent LV diastolic dysfunction after AVR, although
largely underestimated in the past, has recently been shown to be
an independent predictor of hospitalization and mortality [5, 6]
and to carry a substantial risk of the subsequent development of
heart failure also in asymptomatic patients with preserved left
ventricular ejection fraction (LVEF) [7].When present, diastolic dys-
function is graded on three levels that reﬂect the severity and the
progression of the disease. The more advanced the stage is, the
higher the ﬁlling pressures and the worse the outcomes are [7, 8].
Therefore, the early identiﬁcation of LV diastolic dysfunction in
patients without overt symptoms may provide an opportunity to
manage the underlying cause and to prevent progression to con-
gestive heart failure.
Echocardiographic assessment is the gold standard for diastolic
function monitoring; however, it is usually complex and time-
demanding and, sometimes, difﬁcult to interpret. In addition to
echocardiography, B-type natriuretic peptide (BNP) has been
used as a non-invasive marker of LV dysfunction [8, 9].
BNP is a cardiac neurohormone secreted in the cardiac ventri-
cles as a response to wall stress due to ventricular volume expan-
sion and pressure overload. The BNP level reﬂects the severity of
heart failure, is associated with LV structure and function in severe
AS as well as is an independent predictor of complication and
outcome after AVR [10–15]. Moreover, it is strongly related to the
development of symptom onset and increases progressively with
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worsening postoperative New York Heart Association (NYHA)
functional class [11]. In the current literature, however, there are
limited data on the relationship between the BNP level and dia-
stolic dysfunction—or its degree—in patients who underwent AVR
for pure AS. To evaluate the postoperative BNP level as a reliable
biomarker to facilitate the diagnosis of subclinical diastolic dys-
function following AVR, we analysed whether BNP levels rise as a
reﬂection of LV diastolic dysfunction in a large homogeneous
series of patients.
MATERIALS ANDMETHODS
This prospective study was conducted at a single cardiac surgery
centre. Informed consent was obtained from each patient
before enrolment in the study. The study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki, as
reﬂected in a priori approval by the institution’s human research
committee.
Patient selection
Between January 2006 and January 2009, 113 consecutive patients
undergoing AVR for pure AS who fulﬁlled the inclusion criteria
were prospectively selected for this study. Demographic variables
and preoperative, operative and postoperative clinical data were
collected for each patient. The extent of dyspnoea was classiﬁed
according to the NYHA. Clinical and investigation data were used
to deﬁne surgical risk using the European System for Cardiac
Operative Risk Evaluation (EuroSCORE) model [16].
Indications for surgery were mean gradient >50 mmHg and/or
jet velocity >4 m/s and/or aortic valve area <1.0 cm2. Coronary
angiograms were evaluated in all patients before surgery. To
obtain an homogeneous population and avoid any confounding
interference on BNP results, exclusion criteria were as follows: age
over 75 years, evidence of coronary lesions, previous myocardial
infarction, associated valve disease (except trace mitral regurgita-
tion), associated aortic diseases, poor cardiac function as indicated
by an LV ejection fraction (LVEF) of ≤45%, chronic atrial ﬁbrillation,
history of previous heart failure and contraindications to valve re-
placement with bioprostheses. Further exclusion criteria were all
signiﬁcant causes of elevated or reduced BNP levels other than LV
dysfunction as indicated in the current literature: serum creatinine
concentration >150 μmol/l, severe pulmonary disease (acute re-
spiratory distress syndrome, lung disease with right heart failure,
primary pulmonary hypertension and other causes of pulmonary
hypertension) and obesity deﬁned as body mass index (BMI) >30.
Concurrent patients complying with the inclusion criteria and re-
ceiving mechanical valve substitutes were not enrolled to obtain
homogeneity of patient age and postoperative haemodynamic per-
formance (that could inﬂuence BNP levels) [3–4, 17]. Nevertheless,
bioprostheses are not routinely treated with warfarin postopera-
tively in our department, and thus, a potential effect of warfarin on
plasma BNP was avoided.
All study patients underwent physical examination, BNP analysis
and echocardiographic assessment preoperatively, 5 days after
surgery when the patient was presumed to be euvolemic, and at
12 months postoperatively thereafter. Follow-up was ﬁxed at 12
months mainly because prosthetic gradients of bioprostheses
usually change during the ﬁrst postoperative year, with signiﬁcant
impacts on the haemodynamic performance [18].
The AVR was undertaken through a median sternotomy, with
standard cardiopulmonary bypass under mild hypothermia (32°C),
with cold crystalloid cardioplegia. All valves were implanted with
2-0 polyester non-pledget-supported, interrupted, non-everting
mattress sutures.
Operative mortality was deﬁned as death within 30 days after
the operation. Preoperative and surgical variables are summarized
in Table 1.
Echocardiographic measurements and calculations
A comprehensive transthoracic examination was performed
according to the guidelines of the American Society of
Echocardiography (ASE) [19]. When the transthoracic exam was
assessed poor or inadequate, the transoesophageal approach was
employed. LV systolic function was evaluated by the Simpson’s
rule. Left atrial volume was measured by the Simpson’s method in
an apical four- and two-chamber views and indexed for the body
surface area. Timing for measurement was deﬁned at the maximal
expansion of the left atrium. LV mass was calculated from LV linear
dimensions by the ASE-recommended formula based on model-
ling the LV as a prolate ellipse of revolution [20]. LV hypertrophy
was deﬁned as an indexed LV mass (ILVM) of ≥120 g/m2 in men
and ≥100 g/m2 in women [20]. Calculation of relative wall thick-
ness permitted categorization of an increase in LV mass as either
concentric (≥0.42) or eccentric (≤0.42) hypertrophy and allowed
the identiﬁcation of concentric remodelling (normal LV mass with
increased relative wall thickness). The peak and mean prosthetic
gradients were calculated from continuous wave Doppler mea-
surements using the modiﬁed Bernoulli equation. The continuity
equation was used to calculate the effective oriﬁce area indexed
to the patient’s body surface area.
For diastolic function evaluation, mitral ﬂow was recorded at
the tip of mitral leaﬂets in the four-chamber view. Colour ﬂow
Table 1: Preoperative and surgical variables
Variable Patients (N = 113)
Preoperative variables
Age (years) 67.2 ± 8.6
Male sex 77 (68.1%)
Body mass index 24.6 ± 3.1
New York Heart Association Class
I–II 87 (76.9%)
III 26 (23.1%)
Logistic EuroSCORE 5.1 ± 2.4
Surgical variables
Bicuspid aortic valve 15 (13.3%)
Pump time (min) 89.8 ± 14.4
Cross-clamp time (min) 65.7 ± 14.5
Prosthetic valve (mm)
19 41 (36.3%)
21 61 (53.9%)
23 11 (9.8%)
Medtronic Mosaic Ultra porcine valve 88 (77.8%)
Carpentier-Edwards Perimount Magna
pericardial valve
25 (22.2%)
Values expressed as mean ± SD or n (%).
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imaging was used for optimal alignment of the Doppler beam.
Spectral mitral velocity recordings were initially obtained at sweep
speeds of 25–50 mm/s for the evaluation of respiratory variation
of ﬂow velocities, as seen in patients with pulmonary disease. If
variations were not present, the sweep speed was increased to
100 mm/s, at end-expiration, and averaged over three consecutive
cardiac cycles. From the mitral velocity tracings, early ﬂow velocity
(E) and peak velocity during atrial systole (A) were measured. The
E/A ratio was calculated. Pulmonary venous ﬂow velocities,
obtained using the apical four- and two-chamber views, was eval-
uated whenever possible because of their signiﬁcant relationship
with diastolic function. Peak velocities during systole (S) and dia-
stole (D) were measured. The S/D ratio was calculated. Doppler
tissue imaging was taken from the septal mitral annulus to evalu-
ate systolic velocities (S) and early (E) and late (A) diastolic veloci-
ties. The mitral E/E ratio was subsequently calculated.
Diastolic function was evaluated by integrating mitral ﬂow and
pulmonary venous information according to the recommenda-
tions for the evaluation of left ventricular diastolic function by
echocardiography [21]. In addition to E/A, E/E and S/D ratios, the
deceleration time of early ﬁlling velocity and the isovolumetric
relaxation time were also measured to distinguish between
normal diastolic function and mild diastolic dysfunction. Mid-
diastolic ﬂow was considered as an important signal to recognize:
low velocities can occur in normal subjects, but when increased
(>20 cm/s), they often represent markedly delayed LV relaxation
and elevated ﬁlling pressures [22].
Diastolic dysfunction was graded as mild (Grade 1, impaired re-
laxation), moderate (Grade 2, pseudonormal) or severe (Grade 3,
restrictive; Table 2).
Echocardiographic results were interpreted by two experienced
cardiologist blinded to laboratory results.
B-type natriuretic peptide analysis
Rapid quantitative test for BNP assay was performed by means of
the immunoﬂuorometric triage method (Triage, Biosite
Diagnostics, San Diego, CA, USA). Whole venous blood sample (5
ml) was taken after 20 min of rest in the supine position and col-
lected on an ethylenediaminetetraacetic acid (EDTA) tube, and
the BNP level was analysed immediately, following the manufac-
turer’s instructions. The assay is linear throughout the measurable
range of the test. The measurable range of the assay is 5.0–1300
pg/ml, and the intra-assay variations range is between 9.5 and
13.9% for BNP levels of 25 and 1200 pg/ml, respectively. The
average 95% conﬁdence limit of the analytical sensitivity of the
test is <5 pg/ml [95% conﬁdence interval (95% CI) 0.2–4.8 pg/ml].
Statistical analysis
Continuous data are presented as mean and standard deviation
(SD), and categorical data as proportion. Data were analysed by
SPSS version 15 for Windows (SPSS, Inc., Chicago, IL, USA). Stata
6.0 statistical software package was used for receiver operating
characteristic (ROC) analysis. Comparison between continuous
variables was done by the Student’s t-test for normally distributed
features. The Mann–Whitney U-test was used for variables not
normally distributed. Categorical variables were analysed by the
χ2 test. Patients’ echocardiographic characteristics were compared
across the quartiles of BNP distribution either by means of the
Kruskall–Wallis test or by the χ2 test for continuous and categorical
variables, respectively. Pearson’s correlation coefﬁcient was used
to assess the association between BNP levels and echocardio-
graphic data. In addition, pairwise correlations were determined
by using linear regression analysis. Multiway analysis of variance
with correction for serial measurements was performed for echo-
cardiographic data and BPN values. Statistical signiﬁcance was
assumed for P-value <0.05. The ROC curve was determined to
evaluate the reliability of BNP to predict diastolic dysfunction. The
optimal cut-off points for BNP levels were chosen when the sensi-
tivity and speciﬁcity were maximized, and areas under the curve
indicated.
RESULTS
Overall operative mortality was 3.5% (4 of 113). Non-fatal compli-
cations occurred in 9 (7.9%) patients (1 pleural effusion, 3 transient
low output status, 3 ventilatory dependence >36 h and 2 bleeding
requiring surgical revision).
Twelve-month follow-up was 100% complete for mortality and
clinical ﬁndings, and 97.2% for BNP and echocardiographic eva-
luations. Within a follow-up duration of 12 months, 2 (2.6%)
patients died: one suddenly and one of endocarditis. Three more
patients (2.8%) were hospitalized for congestive heart failure. At
follow-up, 55% of patients were receiving b-blockers and 15%
Table 2: Echocardiographic definition of diastolic dysfunction
Mild dysfunction Moderate dysfunction Severe dysfunction
E/A ratio <0.8 0.8–1.0 >2
Deceleration time (ms) >200 150–200 <160
Isovolumetric relaxation time (ms) >100 60–95 <60
S/D ratio S > D S < D S < D
MVAdur/PVAdur MVAdur > PVAdur MVAdur < PVAdur MVAdur < PVAdur
Annular E (cm/s) <8.0 <8.0
E/E ratio <8.0 9–14 >14
A: peak velocity during atrial systole; D: peak velocity during diastole; E: early flow velocity; E: early diastolic velocity; MVAdur: mitral valve A flow duration;
PVAdur: atrial reversal velocity duration; S: peak velocity during systole.
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angiotensin-converting enzyme inhibitors; 30%, b-blockers and
angiotensin-converting enzyme inhibitor therapy started after
surgery. Twelve percent of patients were taking furosemide.
Echocardiographic evaluation
The echocardiographic parameters at baseline and follow-up are
presented in Table 3. The overall interobserver agreement for dia-
stolic dysfunction classiﬁcation was 94%. The intraobserver repro-
ducibility for diastolic dysfunction classiﬁcation was 95%.
At 12-month follow-up, 104 patients were available for echo-
cardiographic evaluations.
Mild to severe diastolic dysfunction occurred preoperatively in
all patients. Twelve months after AVR, a signiﬁcant change in the
distribution of estimated diastolic type was registered when com-
pared with preoperative assessment. LV systolic function was
slightly better (P = 0.06) early after surgery compared with pre-
operative examinations, but no further signiﬁcant improvement
was registered 12 months later. Preoperative cardiac hypertrophy
occurred in 91.1% (103 of 113). At 12-month follow-up, cardiac
hypertrophy persisted in 76.9% of patients available for echocar-
diographic evaluation (80 of 104). Notably, although 1 year after
surgery, an overall reduction in indexed left ventricular mass
values had been registered compared with preoperative values
(P = 0.009), the average value of indexed left ventricular mass
remained persistently above the normal limit. Postoperative
indexed effective oriﬁce area. ≤0.75 cm2/m2 occurred with a sig-
niﬁcant prevalence in patients who had a Medtronic Mosaic Ultra
valve implanted (P < 0.001). Thirteen (11.5%) patients had an
indexed effective oriﬁce area of ≤0.65 cm2/m2.
B-type natriuretic peptide measurement
relationships with echocardiographic ﬁndings
Preoperatively, the mean plasma BNP was 295 ± 125 pg/ml. There
was a dramatic increase immediately postoperatively to 430 ± 342
pg/ml, whereas BNP level sampled on the 12th postoperative
month decreased to 215 ± 148 pg/ml (median 180, interquartile
range 150–250 pg/ml; P = 0.01).
Twelve months after surgery, the mean BNP level was signiﬁ-
cantly higher in patients with LV diastolic dysfunction
(282.5 ± 179.6 pg/ml) than in those with normal diastolic function
(84.3 ± 10.5 pg/ml; P < 0.001). ROC analysis showed that the
optimal cut-off value of the BNP level to detect diastolic dysfunc-
tion 12 months after AVR was 120 pg/ml, with a sensitivity of 91%
(95% CI: 83.23–96.07%) and speciﬁcity of 85% (95% CI: 57.16–
97.80%), with an area under the curve of 0.86. Similarly, BNP
values >300 pg/ml were strongly correlated to echocardiographic
ﬁndings suggestive of moderate or severe diastolic dysfunction
with a sensitivity of 80% (95% CI: 59.29–93.09%) and speciﬁcity of
91% (95% CI: 83.57–96.57%), area under the curve of 0.83. When
patients were categorized according to quartiles of postoperative
BNP values sampled on the 12th postoperative month [90 (60–
135), 160 (140–170), 210 (175–270) and 500 (275–1100) pg/ml], a
fair correlation was found between the value of BNP and the dia-
stolic dysfunction grade: the lower quartile of BNP distribution
was related to normal diastolic function, the second and third
quartiles to mild diastolic dysfunction and the upper quartile to
moderate or severe diastolic dysfunction (P < 0.001 for all com-
parison; Fig. 1). The relationships between BNP values and echo-
cardiographic parameters, evaluated by means of Pearson’s
correlation, are reported in Table 4.
In addition, for each patient identiﬁed as having mild or
moderate to severe diastolic dysfunction 12 months after
surgery, the E/E ratio values were forced in the linear regression
model for correlation to BNP values. The grade of diastolic dys-
function was strictly associated with BNP values, as reﬂected by
signiﬁcant correlations between BNP and E/E ratio ≤0.8
(R2 = 0.56; y = −354.9x + 436, P < 0.001) and BNP and E/E ratio
from 0.8 to 2.4 (R2 = 0.93; y = 555.9x − 296.8, P < 0.001; Fig. 2A
and B). Finally, there was no signiﬁcant correlation between the
NYHA class and BNP levels, probably as a reasonable conse-
quence of preserved systolic function and good gradient at
12-month follow-up. This was, moreover, not surprising taking
Table 3: Echocardiographic and functional parameters at baseline and follow-up
Baseline
(N = 113)
5 days after surgery
(N = 110)
12 months after surgery
(N = 104)
P-value
Systolic blood pressure (mmHg) 135 ± 12 125 ± 15 138 ± 14 0.07
Diastolic blood pressure (mmHg) 85 ± 8 75 ± 5 83 ± 5 0.009
Left ventricular ejection fraction (%) 52.8 ± 5.7 54.1 ± 4.6 54.2 ± 5.1 0.05
Indexed left ventricular mass (g/m2) 175.9 ± 45.3 174 ± 45.7 159.2 ± 42.9 0.009
Peak gradient (mmHg) 95.6 ± 31.5 30.6 ± 6.3 25.1 ± 4.4 <0.001
Mean gradient (mmHg) 55.7 ± 13.4 15.1 ± 4.3 13.1 ± 3.7 <0.001
Left ventricular diastolic diameter (mm) 46.2 ± 5.7 45.8 ± 5.9 44.9 ± 5.8 0.06
Left ventricular systolic diameter (mm) 29.6 ± 5.8 30.2 ± 6.1 31.1 ± 5.9 0.06
Indexed left atrial volume (ml/m2) 35.2 ± 9.5 36.4 ± 10.9 29.1 ± 6.3 <0.001
Diastolic function
Normal – – 14 (13.4%) <0.001
Mild (impaired relaxation) 28 (24.7%) – 65 (62.5%) <0.001
Moderate (pseudonormal) 71 (62.8%) – 17 (16.4%) <0.001
Severe (restrictive) 14 (12.5%) – 8 (7.7%) 0.3
B-type natriuretic peptide (pg/ml) 295 ± 125 430 ± 242 245 ± 168 0.01a
Indexed effective orifice area cm2/m2 (mean) – 0.75 ± 0.07 0.76 ± 0.06 <0.001
Values expressed as mean ± SD or n (%).
aBaseline vs 12 months after surgery.
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into account that more than two-third of our patients were in
NYHA Class I or II preoperatively, and thus, there was little
room for NYHA class improvement in these patients, even
though plasma BNP decreased signiﬁcantly.
DISCUSSION
In the present study, we tried non-invasively to identify isolated
LV diastolic dysfunction 1 year after successful AVR and to demon-
strate the potential of plasma BNP measurement for the sensitive
detection of this condition. The results can be summarized as
follows: (i) BNP levels were higher before operation in patients
undergoing AVR for pure AS despite relatively preserved LVEF; (ii)
early after operation, there was a dramatic transient increase in
BNP levels; (iii) at 12-month follow-up, BNP levels decreased
signiﬁcantly compared with the preoperative levels, although
normal values were reached in only few patients within
12 months; (iv) BNP levels reﬂected LV diastolic function and its
severity also in asymptomatic patients; (v) BNP values >120 pg/ml
12 months after AVR were strongly correlated to echocardio-
graphic ﬁndings suggestive of diastolic dysfunction; (vi) BNP
values >300 pg/ml were strongly correlated to echocardiographic
ﬁndings suggestive of moderate or severe diastolic dysfunction.
Following AVR, the afterload of the left ventricle is immediately
reduced, and this leads to a recovery of wall stress, LV ejection
time, LV volume, coronary perfusion and the load of the left
atrium [4, 17, 23]. Conversely, persistence of LV hypertrophy is
common after AVR and its regression is a slow process that takes
years after correction of the primary haemodynamic abnormality
and may continue for decades after surgery [23]. LV hypertrophy,
stiffness (or reduced compliance) and subsequently impaired
myocardial relaxation are considered the main determinant of
postoperative diastolic dysfunction, which is worldwide consid-
ered predictive of the long-term adverse postoperative outcome
[2, 5, 6, 23].
Echocardiography is the method of choice for diastolic function
evaluation; however, it is usually complex and time-demanding
and carries potential errors, particularly in distinguishing normal
and pseudonormal stages. Tissue Doppler imaging, used in add-
ition to traditional echocardiographic variables, minimizes these
potential errors, but, in general, the deﬁnition of diastolic dysfunc-
tion (and the assessment of the stage) is difﬁcult, and sometimes
the measurements are less reproducible. In our experience, we
found non-negligible intra- and interobserver variabilities of 5
and 6%, respectively, which is in line with those known from the
literature.
In addition to echocardiography, BNP assessment has been
validated as a highly sensitive and accurate method for the detec-
tion of LV systolic and diastolic dysfunction [24] and has emerged
as a key biomarker for the diagnosis, evaluation and management
of congestive heart failure [25]. In surgical patients with AS under-
going AVR, the BNP level has been identiﬁed as a strong predictor
of early and long-term postoperative outcomes [9–14].
In the setting of LV diastolic function, we found signiﬁcant cor-
relations between the BNP level and echocardiographic evidence
Figure 2: Diastolic function parameter (E/E ratio) 12 month after AVR analysed
for correlation to BNP: (A) patients with mid-diastolic dysfunction and (B)
patients with moderate or severe diastolic dysfunction.
Figure 1: Comparisons between plasma BNP level and grade of LV diastolic
function related to 12 months postoperatively. Box deﬁnes the interquartile
range, with the mean indicated by the crossbar. The error bars indicate the SD.
Table 4: Relationships between BNP values and
echocardiographic parameters
r-value P-value
BNP
Left ventricular ejection fraction (%) −0.2 0.09
Indexed effective orifice area (cm2/cm2) −0.68 0.001
Peak gradient 0.21 0.3
Mean gradient 0.15 0.52
Indexed left ventricular mass (g/m2) 0.31 0.04
Indexed left atrial volume 0.52 0.006
E/A 0.81 <0.001
E/E 0.83 <0.001
S/D −0.69 <0.001
Isovolumetric relaxation time (ms) −0.72 <0.001
Deceleration time (m/s) −0.65 0.003
Relationship evaluated by Pearson’s correlation.
E/A: early flow velocity (E) to peak atrial velocity (A) ratio; E/E:
transmitral early diastolic velocity (E) to myocardial early diastolic
velocity (E) of the lateral mitral annulus by tissue Doppler; S/D: peak
systolic velocity (S) to diastolic velocity (D) ratio.
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of postoperative diastolic dysfunction. As a further result, this
study demonstrated that BNP values are directly related to several
transmitral ﬂow parameters and tissue Doppler ﬁndings indicative
of impaired LV diastolic function. These results were substantiated
by the signiﬁcant linear correlation between E/E ratio and BNP
levels in patients with mild or moderate to severe diastolic dys-
function. Using ROC analysis, we found that a BNP level of >120
pg/ml was a discriminative threshold for normal or impaired dia-
stolic function after AVR. Similarly, a BNP level of >300 pg/ml was
a relevant cut-off level, leading to higher sensitivity and speciﬁcity
in terms of identifying moderate or severe diastolic dysfunction.
As a consequence, BNP values, coupled with LV diastolic status,
may bring more speciﬁc evaluation of isolated LV diastolic dys-
function and could be used as a simple, not operator-dependent,
relatively inexpensive and reproducible tool for assessing LV func-
tion after AVR and for monitoring the evolution of diastolic dys-
function after AVR.
The clinical relevance and the prognostic value of BNP have
been well elucidated by Berger et al. who found that an elevated
hormone level was associated with a signiﬁcantly higher number
of any-cause death in symptomatic patients who underwent AVR
for AS [10]. More recently, Pedrazzini et al. [12] demonstrated that
higher preoperative BNP values (>312 pg/ml) were strong predic-
tors of hospital mortality and, more importantly, long-term sur-
vival and were more accurate in predicting postoperative adverse
outcome compared with logistic EuroSCORE or echocardiograph-
ic evaluation. These ﬁndings have been recently substantiated by
Iwahashi et al. [11] who conﬁrmed that BNP >312 pg/ml was ac-
curate enough for predicting perioperative complications and was
associated with the risk of major cardiac and cerebrovascular
events after AVR.
These results, taken together, provide the necessary clinical
support to our study, considering that BNP appears to reﬂect the
actual haemodynamic state and could predict non-invasively the
progression of diastolic dysfunction from one class to the next
and, consequently, the transition from compensated to decom-
pensated heart status. Thus, BNP assessment may represent an im-
portant adjunct for the early and adequate recognition of LV
dysfunction and may contribute to medical treatment optimiza-
tion before the development of symptoms that are non-speciﬁc
and subtle at onset and often difﬁcult to evaluate clinically or by
echocardiography.
The study has several limitations: (i) there was always a potential
error in interpreting diastolic function echocardiographically, par-
ticularly in distinguishing normal and pseudonormal; however, a
number echocardiographic ﬁndings were evaluated in the present
study in order to minimize possible bias; (ii) we were not able,
with few events, to draw any meaningful conclusions on the rela-
tionship between BNP values and postoperative deaths or need
for hospitalization; (iii) patient follow-up was performed at 12
months after surgery, so the results need a further long-term val-
idation.
The present study indicates the relationship between BNP and
LV diastolic function after AVR for AS. The serial measurements of
BNP may complement echocardiographic and clinical evaluation,
particularly when symptoms are unclear or when LV function is
difﬁcult to interpret. However, further large prospective studies
are needed to determine whether serial measurements of BNP
levels can be used to monitor disease progression in the late
stages and whether it may be useful as an additional tool for plan-
ning an effective pharmacological strategy in preventing LV deteri-
oration.
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